• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Life Science Market
Life Science News
Life Science Stocks
  • Life Science Market
  • Life Science News
  • Life Science Stocks

New Study Shows Complications Rare in Test-tube Fertility Procedures

Charlotte McLeod
Jan. 06, 2015 03:54PM PST
Life Science Investing

The Associated Press reported that a new American 12-year study shows that complications are rare for women undergoing test-tube fertility procedures. Most frequently problems happen when drugs are used to stimulate ovaries, but even then fatalities don’t usually arise.

The Associated Press reported that a new American 12-year study shows that complications are rare for women undergoing test-tube fertility procedures. Most frequently problems happen when drugs are used to stimulate ovaries, but even then fatalities don’t usually arise.

As quoted in the market news:

Over-stimulated ovaries occurred in 154 out of every 10,000 pregnancy attempts; rates of other complications were less than 10 per 10,000 attempts. There were 58 deaths reported during the 2000-11 study. The study lacks information on their causes, and with more than 1 million pregnancy attempts involved, the results are reassuring, said Dr. Jennifer Kawwass, an Emory University assistant professor and the lead author.

The study is the first large-scale effort to quantify risks for U.S. patients undergoing these treatments, Kawwass said. Results were published in Tuesday’s Journal of the American Medical Association.

Click here to read the full report from The Associated Press.

life-science-investing
The Conversation (0)

Go Deeper

AI Powered
Life Science Outlook: World Edition

Life Science Outlook: World Edition

2025 Life Science Outlook: Australia Edition

2025 Life Science Outlook: Australia Edition

Latest News

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

More News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Life Science Investing Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES